Under the agreement, Myung In Pharma is set to contribute 10% of the subjects to be enrolled for Newron's upcoming trial.

Have an issue with your financial planner or looking for a new one? Email questions or concerns to [email protected].

Despite a cautious deal market and continuing economic and political uncertainty as 2024 began, Dechert remained active in the financial services ...